181 related articles for article (PubMed ID: 7584882)
1. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens.
Eriksson S; Eriksson A; Stege R; Carlström K
Calcif Tissue Int; 1995 Aug; 57(2):97-9. PubMed ID: 7584882
[TBL] [Abstract][Full Text] [Related]
2. Adrenocortical function in prostatic cancer patients: effects of orchidectomy or different modes of estrogen treatment on basal steroid levels and on the response to exogenous adrenocorticotropic hormone.
Carlström K; Stege R
Urol Int; 1990; 45(3):160-3. PubMed ID: 2161578
[TBL] [Abstract][Full Text] [Related]
3. Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma.
Carlström K; Stege R; Henriksson P; Grande M; Gunnarsson PO; Pousette A
Prostate; 1997 May; 31(3):193-7. PubMed ID: 9167772
[TBL] [Abstract][Full Text] [Related]
4. Comparison of endocrine and radiation therapy in locally advanced prostatic cancer.
Aro J; Haapiainen R; Kajanti M; Rannikko S; Alfthan O
Eur Urol; 1988; 15(3-4):182-6. PubMed ID: 3063541
[TBL] [Abstract][Full Text] [Related]
5. Orchiectomy, estrogen therapy and radiotherapy in locally advanced (T3-4 M0) prostatic cancer.
Aro J; Haapiainen R; Kajanti M; Rannikko S; Alfthan O
Scand J Urol Nephrol Suppl; 1988; 110():103-7. PubMed ID: 3187397
[TBL] [Abstract][Full Text] [Related]
6. Urethral obstruction secondary to carcinoma of prostate: response to endocrine treatment.
Varenhorst E; Alund G
Urology; 1985 Apr; 25(4):354-6. PubMed ID: 3157256
[TBL] [Abstract][Full Text] [Related]
7. Effects of orchidectomy and different modes of high dose estrogen treatment on circulating "free" and total 1,25-dihydroxyvitamin D in patients with prostatic cancer.
Hagenfeldt Y; Carlström K; Berlin T; Stege R
J Steroid Biochem Mol Biol; 1991 Aug; 39(2):155-9. PubMed ID: 1888674
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population.
Aro J
Prostate; 1991; 18(2):131-7. PubMed ID: 2006119
[TBL] [Abstract][Full Text] [Related]
9. Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study.
Haapiainen R; Rannikko S; Alfthan O
Br J Urol; 1986 Oct; 58(5):528-33. PubMed ID: 3779355
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment hormone levels in prostatic cancer.
Haapiainen R; Rannikko S; Alfthan O; Adlercreutz H
Scand J Urol Nephrol Suppl; 1988; 110():137-43. PubMed ID: 3187401
[TBL] [Abstract][Full Text] [Related]
11. Deteriorated arterial supply to the lower limb during oral oestrogen therapy of patients with prostatic carcinoma.
Henriksson P; Linde B
Urol Int; 1994; 53(2):74-8. PubMed ID: 7801420
[TBL] [Abstract][Full Text] [Related]
12. Early results of the Finnish Multicentre Study of Prostatic Cancer (Finnprostate).
Haapiainen R; Rannikko S; Ruutu M; Ala-Opas M; Aro J; Ervasti J; Hansson E; Hurme K; Juusela H; Mäkinen J
Ann Chir Gynaecol; 1985; 74(6):277-83. PubMed ID: 4096480
[TBL] [Abstract][Full Text] [Related]
13. Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen.
Henriksson P; Johansson SE
Am J Epidemiol; 1987 Jun; 125(6):970-8. PubMed ID: 3578255
[TBL] [Abstract][Full Text] [Related]
14. [Administration of 1 alpha-OH vitamin D3 and calcium prevents bone mass loss in patients with advanced prostatic carcinoma after orchidectomy treated with complete androgenic blockade].
Tałalaj M; Kapitan-Malinowska B; Debski K; Nowakowski R; Marcinowska-Suchowierska E; Witeska A
Endokrynol Pol; 2005; 56(3):225-32. PubMed ID: 16350714
[TBL] [Abstract][Full Text] [Related]
15. Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males.
Berglund L; Carlström K; Stege R; Gottlieb C; Eriksson M; Angelin B; Henriksson P
J Clin Endocrinol Metab; 1996 Jul; 81(7):2633-7. PubMed ID: 8675589
[TBL] [Abstract][Full Text] [Related]
16. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J
Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
Stege R; Grande M; Carlström K; Tribukait B; Pousette A
Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
[TBL] [Abstract][Full Text] [Related]
18. Correlation of pretreatment plasma levels of estradiol and sex-hormone-binding globulin-binding capacity with clinical stage and survival of patients with prostatic cancer.
Haapiainen R; Rannikko S; Adlercreutz H; Alfthan O
Prostate; 1986; 8(2):127-37. PubMed ID: 3952023
[TBL] [Abstract][Full Text] [Related]
19. Hormonal regulation of circulating C-reactive protein in men.
Kovacs A; Henriksson P; Hamsten A; Wallén H; Björkegren J; Tornvall P
Clin Chem; 2005 May; 51(5):911-3. PubMed ID: 15855670
[No Abstract] [Full Text] [Related]
20. Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma.
Tomić R
Scand J Urol Nephrol Suppl; 1983; 77():1-37. PubMed ID: 6426040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
